Is Tirzepatide considered natty?

Tirzepatide is generally regarded as compatible with natural bodybuilding. Most sanctioning bodies do not prohibit its therapeutic use, though rules vary by federation.

Is Tirzepatide on the WADA prohibited list?

As of the current prohibited list, Tirzepatide is not explicitly banned by WADA, though regulations can change. Always verify against the current year's WADA prohibited list before competition.

How is Tirzepatide administered?

Tirzepatide is typically administered via: subcutaneous injection. Dosage and administration protocols vary; see the Dosage section for details.

Tirzepatide - Retapedia | Natty or Not?

Medical disclaimer. This article is for informational purposes only and does not constitute medical advice. Consult a qualified clinician before considering any compound discussed below. See Retapedia : Medical disclaimer.

Tirzepatide
Identification
Structure of Tirzepatide. 39-aa dual GIP/GLP-1 agonist with Aib at positions 2 and 13, γGlu–2×OEG–C20 diacid lipidation on Lys20, and a C-terminal amide. Source: Wikimedia Commons.
Class	Modified peptide
PubChem CID	156588324
Other names	Tirzepatide · GIP/GLP-1 dual agonist
Trade names	Mounjaro Zepbound
Administration
Routes	Subcutaneous injection
Status
Verdict	Natty
WADA	Not prohibited^[17]
Article meta
Slug	`tirzepatide`
Last edited	July 17, 2026
Tags	fat loss, weight loss, diabetes, cardiovascular, sleep apnea, subcutaneous

Tirzepatide (also known as Tirzepatide or GIP/GLP-1 dual agonist) is a therapeutically researched peptide studied for its effects on fat loss, weight loss, diabetes. FDA-approved dual GIP/GLP-1 agonist (Mounjaro/Zepbound) with superior 21% weight loss, first OSA medication, excellent diabetes control. GI side effects common.

Tirzepatide is an FDA-approved dual GIP/GLP-1 receptor agonist manufactured by Eli Lilly as Mounjaro (type 2 diabetes, 2.5-15mg weekly) and Zepbound (obesity and obstructive sleep apnea, 2.5-15mg weekly). Unique imbalanced agonist with greater GIP receptor engagement than GLP-1, plus biased GLP-1 agonism favoring cAMP generation over β-arrestin recruitment, enhancing insulin secretion. SURMOUNT trials demonstrated exceptional weight loss: 20.9% at 72 weeks (15mg dose), with 50-57% of participants achieving ≥20% weight loss.

Natty status

Tirzepatide is generally regarded as compatible with natural bodybuilding, though competitive federations may differ. See § Natty status.

Contents [hide]

1 Overview
2 Mechanism of action
3 Reported effects
4 Dosage and administration
5 Natty status
6 Research
7 Related compounds
8 References
9 External links

Overview

SURMOUNT-4 showed 25.3% mean weight reduction long-term.

Unprecedented diabetes efficacy in SURPASS trials with HbA1c reductions of 1.9-2.6% and weight loss of 6.6-13.9kg, superior to semaglutide 1mg.

December 2024 FDA approval as first medication for moderate-to-severe obstructive sleep apnea in adults with obesity, reducing breathing disruptions by 25-29 per hour (5x more effective than placebo).

Cardiovascular meta-analysis showed HR 0.80 for MACE-4, with SURPASS-4 showing HR 0.50 at 15mg dose.

Common side effects are gastrointestinal (nausea, vomiting, diarrhea 16.24% vs 8.63% placebo), typically mild-to-moderate, transient, occurring during dose escalation. 2024 systematic review found no association with pancreatitis.

Gradual titration every 4 weeks (2.5mg steps) minimizes adverse events.

Available in 6 strengths: 2.5mg, 5mg, 7.5mg, 10mg, 12.5mg, 15mg.

Mechanism of action

Dual GIP/GLP-1 agonist. Reduces appetite for up to 21% weight loss. Improves blood sugar and diabetes control. First drug approved for obstructive sleep apnea. GI side effects common.

Reported effects

Effects reported in the literature and from preclinical models include:

As a dual GIP/GLP-1 receptor agonist, tirzepatide produces substantial, dose-dependent weight loss of roughly 5-21% over up to 72 weeks in adults with obesity, driven largely by fat-mass reduction and exceeding most other anti-obesity drugs in network meta-analysis. ^[3]^[4]^[7]^[9]^[14]^[16] FDA approved
Tirzepatide delivers robust, dose- and duration-dependent glycemic control with marked HbA1c reductions in type 2 diabetes via improved insulin secretion, delayed gastric emptying, and reduced appetite. ^[3]^[4]^[9]^[14] FDA approved
In obese patients with heart failure with preserved or mildly reduced ejection fraction, tirzepatide reduces heart failure hospitalizations and the composite of cardiovascular death or worsening heart failure events while improving symptoms and functional capacity, though overall heart failure risk reduction is not statistically significant across pooled trials. ^[2]^[8]^[10]^[12]^[16]^[1] Phase III
In obese patients with obstructive sleep apnea, dual GIP/GLP-1 agonist therapy lowers the apnea-hypopnea index alongside weight loss and reduced cardiometabolic risk. ^[11]^[14] FDA approved
Tirzepatide's main tolerability concerns are common gastrointestinal adverse events that drive a roughly 4-10% treatment discontinuation rate, plus notable loss of lean/skeletal-muscle mass during weight loss that raises sarcopenia risk, especially in older adults. ^[3]^[6]^[9]^[15]^[16] Phase III
Randomized-trial meta-analyses found no statistically significant increase in thyroid cancer or breast cancer risk with incretin-based therapies including tirzepatide, though limited follow-up cannot exclude a clinically relevant increase. ^[5]^[13] Phase III

Evidence grades: FDA approved Phase III Phase II Phase I Preclinical Anecdotal

Dosage and administration

⚠

Dosage information is included for encyclopedic purposes only. Retapedia does not provide medical advice. See Retapedia : Medical disclaimer.

General

Week 1-4: 2.5mg once weekly (subcutaneous, starting dose)
Week 5-8: 5.0mg once weekly
Week 9-12: 7.5mg once weekly (optional step)
Week 13-16: 10mg once weekly
Week 17-20: 12.5mg once weekly (optional step)
Week 21+: 15mg once weekly (maximum dose)
Escalate by 2.5mg every 4 weeks minimum
Do not increase faster than 2.5mg per 4 weeks

Maintenance

5mg, 10mg, or 15mg based on response/tolerability

Available strengths

2.5, 5, 7.5, 10, 12.5, 15mg per 0.5mL

Natty status

See also: Peptide § Natty status

Tirzepatide is generally regarded as compatible with the natty designation, particularly when used for therapeutic healing purposes. Opinions vary across natural bodybuilding federations, and athletes who compete should consult the rulebook of their respective sanctioning body.^[17]